Inpatient Transition From Intravenous to Inhaled Treprostinil in a Pediatric Patient

Overview

Journal J Pediatr Pharmacol Ther

Specialty Pediatrics

Date 2023 Feb 13

PMID 36777978

Authors

David Procaccini

Dennis Delany

Abigail Self

Patricia Lawrence Kane

John D Coulson

Affiliations

Soon will be listed here.

Abstract

We report a case of a 7-year old male with idiopathic pulmonary arterial hypertension, successfully transitioned from an intravenous infusion to inhaled treprostinil during inpatient admission, after his intentional removal of multiple central venous catheters. He had no clinical, echocardiographic, or serum biomarker evidence of loss of control of pulmonary arterial hypertension during the 4-day transition. The patient was discharged home without complications, and 3 weeks after discharge the patient's pulmonary hypertension remained well controlled per clinical and echocardiographic evidence, including a significantly improved 6-minute walk distance test.

References

Laliberte K, Arneson C, Jeffs R, Hunt T, Wade M . Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers. J Cardiovasc Pharmacol. 2004; 44(2):209-14. DOI: 10.1097/00005344-200408000-00010. View

Galie N, McLaughlin V, Rubin L, Simonneau G . An overview of the 6th World Symposium on Pulmonary Hypertension. Eur Respir J. 2018; 53(1). PMC: 6351332. DOI: 10.1183/13993003.02148-2018. View

Raina A, Coons J, Kanwar M, Murali S, Sokos G, Benza R . Transitioning from parenteral treprostinil to inhaled treprostinil in patients with pulmonary arterial hypertension. Pulm Circ. 2013; 3(1):116-20. PMC: 3641714. DOI: 10.4103/2045-8932.109926. View

Rich J, Glassner C, Wade M, Coslet S, Arneson C, Doran A . The effect of diluent pH on bloodstream infection rates in patients receiving IV treprostinil for pulmonary arterial hypertension. Chest. 2011; 141(1):36-42. DOI: 10.1378/chest.11-0245. View

Krishnan U, Takatsuki S, Ivy D, Kerstein J, Calderbank M, Coleman E . Effectiveness and safety of inhaled treprostinil for the treatment of pulmonary arterial hypertension in children. Am J Cardiol. 2012; 110(11):1704-9. PMC: 3508003. DOI: 10.1016/j.amjcard.2012.07.037. View

Kallen A, Lederman E, Balaji A, Trevino I, Petersen E, Shoulson R . Bloodstream infections in patients given treatment with intravenous prostanoids. Infect Control Hosp Epidemiol. 2008; 29(4):342-9. DOI: 10.1086/529552. View

Khair R, Nwaneri C, Damico R, Kolb T, Hassoun P, Mathai S . The Minimal Important Difference in Borg Dyspnea Score in Pulmonary Arterial Hypertension. Ann Am Thorac Soc. 2016; 13(6):842-9. PMC: 5018926. DOI: 10.1513/AnnalsATS.201512-824OC. View

Al-Qadi M, LeVarge B, Ford H . Epidemiology, Pathogenesis, and Clinical Approach in Group 5 Pulmonary Hypertension. Front Med (Lausanne). 2021; 7:616720. PMC: 8026868. DOI: 10.3389/fmed.2020.616720. View

McLaughlin V, Benza R, Rubin L, Channick R, Voswinckel R, Tapson V . Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. 2010; 55(18):1915-22. DOI: 10.1016/j.jacc.2010.01.027. View

10.

Hall K, Ogawa M, Sakarovitch C, Hopper R, Adamson G, Hanna B . Subcutaneous and Intravenous Treprostinil Pharmacokinetics in Children With Pulmonary Vascular Disease. J Cardiovasc Pharmacol. 2019; 73(6):383-393. DOI: 10.1097/FJC.0000000000000674. View

11.

Simonneau G, Montani D, Celermajer D, Denton C, Gatzoulis M, Krowka M . Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J. 2018; 53(1). PMC: 6351336. DOI: 10.1183/13993003.01913-2018. View

12.

Rosenzweig E, Abman S, Adatia I, Beghetti M, Bonnet D, Haworth S . Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management. Eur Respir J. 2018; 53(1). PMC: 6351335. DOI: 10.1183/13993003.01916-2018. View

13.

McLaughlin V, Archer S, Badesch D, Barst R, Farber H, Lindner J . ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American.... J Am Coll Cardiol. 2009; 53(17):1573-619. DOI: 10.1016/j.jacc.2009.01.004. View

14.

de Jesus Perez V, Rosenzweig E, Rubin L, Poch D, Bajwa A, Park M . Safety and efficacy of transition from systemic prostanoids to inhaled treprostinil in pulmonary arterial hypertension. Am J Cardiol. 2012; 110(10):1546-50. DOI: 10.1016/j.amjcard.2012.07.012. View

15.

Sahay S . Evaluation and classification of pulmonary arterial hypertension. J Thorac Dis. 2019; 11(Suppl 14):S1789-S1799. PMC: 6783722. DOI: 10.21037/jtd.2019.08.54. View

16.

Barst R, Galie N, Naeije R, Simonneau G, Jeffs R, Arneson C . Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J. 2006; 28(6):1195-203. DOI: 10.1183/09031936.06.00044406. View

17.

Enderby C, Soukup M, Al Omari M, Zeiger T, Burger C . Transition from intravenous or subcutaneous prostacyclin therapy to inhaled treprostinil in patients with pulmonary arterial hypertension: a retrospective case series. J Clin Pharm Ther. 2014; 39(5):496-500. DOI: 10.1111/jcpt.12170. View

18.

Abman S, Hansmann G, Archer S, Ivy D, Adatia I, Chung W . Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society. Circulation. 2015; 132(21):2037-99. DOI: 10.1161/CIR.0000000000000329. View